In PEPCAD-DES late loss as well as the need for repeat revascularization was significantly reduced with drug coated balloon (DCB) angioplasty compared with plain old balloon angioplasty (POBA) for drug-eluting stent (DES) restenosis (clinical trials.gov NCT00998439). We now evaluated whether the use of DCB is different in paclitaxel DES restenosis or non-paclitaxel DES restenosis. Methods: 110 patients with a DES restenosis of either Sirolimus-(SES), Everolimus-(EES) or Paclitaxel-eluting (PES) stents in a native coronary artery with indication for percutaneous coronary intervention with a reference diameter ranging from 2.5mm to 3.5 mm and lesion length less or equal to 22 mm were randomized to treatment with either DCB or POBA in six centers. 38 patients were randomized to POBA and 72 patients to DCB. Patients suffered from repeat restenotic lesion (Ն2nd) in 55.6% (Nϭ50) in DCB group and 52.6% (Nϭ20) in POBA population. In the DCB group restenosis was located in SES (Nϭ41, 56.9%), PES (Nϭ20, 27.7%) or EES (Nϭ11, 15.3%). Numbers for POBA group were SES (Nϭ27, 71.1%), PES (Nϭ7, 18.4%) or EES (Nϭ3, 13.2%). Results: DCB as compared with POBA significantly reduced late loss in PES restenosis and non-PES restenosis with 0.46Ϯ0.50mm vs. 1.58Ϯ1.03mm (pϭ0.002) and 0.31Ϯ0.54mm vs. 0.90Ϯ0.67mm (pϽ0.001), respectively. Furthermore, TLR rates were lower with DCB versus POBA for PES restenosis (5% vs. 57.1%, pϽ0.001) and non-PES restenosis (18.5% vs. 32.3%, pϭ0.002). Late loss did not differ for PES versus SES lesions with DCB treatment (0.46 vs. 0.31mm, pϭ0.123). DCB was superior to POBA for treatment of a first restenosis and for Նsecond restenosis with a late loss of 0.35Ϯ0.60mm vs. 0.65Ϯ0.60mm (pϭ0.128) and 0.49Ϯ0.61mm vs. 1.34Ϯ0.76mm (pϽ0.001), respectively. Conclusions: Paclitaxel coated balloon angioplasty was superior to POBA for treatment of PES and non-PES restenosis. DCB effect on late loss did not differ between type of DES. Background: Drug-eluting stents constitute a major achievement in preventing restenosis, concerns remain regarding the increased inflammatory and thrombogenic responses associated with the polymers used. This analysis focuses on outcomes in patients receiving the polymer-free microporous rapamycin-eluting stent system YUKON-Choice (Yukon-DES, Translumina, Hechingen, Germany). Methods: From 01/2006-09/2008 all consecutive patients (pts) receiving Yukon-DES (Ն2,5mm diameter) were prospectively enrolled in our registry. 6-months angiographic and long-term clinical outcomes were analysed. The primary endpoint was cumulative long-term major adverse cardiac events (MACE). Results: 701 pts with 724 lesions (1050 stents) were included in our registry. Mean age was 65.7Ϯ10 years (73% male). Risk factors included hypercholesterolemia (57.6%), hypertension (74.8%), and diabetes (35.5%); table 1. Indication for percutaneous coronary intervention was acute coronary syndrome in 32.2%. 76% of the lesions were of Type B2/C, target vessel was left anterior descending artery in 35.2%, and 23.2% were chronic total occlusions. Lesion length was 24.6Ϯ5.2 mm and mean stent diameter was 2.8Ϯ0.4 mm; table 1. A total of 511 pts (72%) underwent 6-months angiographic follow-up, binary restenosis was noted in 23.5%. At 5 years clinical outcomes of 625/701 (89%) followed patients were: cardiac death 5.8%; myocardial infarction 3.4%; and target vessel revascularisation 24.6%. The cumulative five-year incidence of MACE was 35.4% (6.7% per year). Incidence of stent thrombosis (ST) was 2.86% (30/1050) [definite 0.86%;
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Abstract Withdrawn Background: Proximal coronary artery disease is associated with a poorer prognosis compared to disease in the distal coronary arteries. PCI of a culprit lesion in the left anterior descending artery (LAD) may have a worse prognosis than PCI of the proximal left circumflex (LCX) or right coronary arteries (RCA). The possible disparity in risk may be attenuated by stenting strategy. The aim of the present study was to evaluate outcome after PCI of solitary proximal stenoses of the LAD as compared to the LCX and the RCA. 
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